Good News | Jingxin Pharmaceutical's innovative drug Dimdazenil has been approved for market launch, with Clinflash continuing to support pharmaceutical innovation!

Recently, the National Medical Products Administration (NMPA) of China announced the approval of Zhejiang Jingxin Pharmaceutical Co., Ltd's category 1 innovative drug Dimdazenil capsules (EVT201 capsules) for market launch. As the first small molecule innovative drug approved for market launch by Jingxin Pharmaceuticals, Dimdazenil capsules partially activate GABAA receptors, producing a sleep-promoting effect and providing a new treatment option for patients with insomnia disorders.

【Image source: Official website of the China NMPA】

Since 2015, Clinflash has closely collaborated with Jingxin Pharmaceutical, using high-quality digital solutions and highly competent support teams to address various challenges in multiple projects over the 9-year cooperation period，which has laid a solid and reliable data foundation for drug approval, effectively accelerating the commercialization process of innovative drug products by Jingxin Pharmaceutical!

During the initial research and development phase of the Dimdazenil project, Clinflashi established a collaboration with Jingxin Pharmaceutical, swiftly launching the Clinflash EDC electronic data capture system in accordance with project requirements. This initiative enhanced the speed of data entry and review, garnering recognition from the Jingxin team.

Due to this recognition, Clinflash's subsequent independent development of the Clinflash IRT randomization and supply management system, as well as the Clinflash Safety pharmacovigilance database system, were also integrated into the research and development process of this innovative drug. With the robust support of the various Clinflash systems, Clinflash team could swiftly accomplish tasks such as random configuration review, data auditing, SMP drafting, project training, and safety information management, continuously empowering the entire project operation process.

With Clinflash's support, the operational efficiency of the Dimdazenil project saw a significant improvement, successfully meeting the corresponding milestones as per various time requirements. Furthermore, Clinflash team also provided multiple suggestions and assistance in scheme review and SMP development to address the diverse clinical trial guidelines and regulations that changed during the research and development cycle, ensuring project compliance.

As the leading provider of cloud solutions, Clinflash possesses a deep understanding of the difficulties and challenges that may arise in pharmaceutical innovation. Committed to applying the accumulated experience from past projects to future endeavors, Clinflash continues to empower the innovation of Chinese medicine.

We sincerely look forward to collaborating with more pharmaceutical colleagues, leveraging professional digital technologies and dedicated support teams to assist various pharmaceutical products in smoothly passing regulatory inspections, thus providing a diverse range of treatment options for more patients.